Search research articles
Contact Us
Filters
Showing results (221-230 of 512) with videos related to
Page
of 52
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 14, 2025
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial
K L Jhaveri, P Neven, M L Casalnuovo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2010
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer
A D Seidman, A Brufsky, R H Ansari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 7, 2022
ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)
S Paluch-Shimon, F Cardoso, A H Partridge, et al.
ESMO Open
|
November 19, 2025
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study
J-P Metges, K Kato, J-M Sun, et al.
Breast Cancer Research and Treatment
|
November 15, 2014
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer
C Palmieri, S Cleator, L S Kilburn, et al.
ESMO Open
|
April 10, 2026
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial
G Curigliano, J O'Shaughnessy, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
N Harbeck, S Modi, L Pusztai, et al.
American Journal of Hematology
|
April 3, 2001
Correlation of hematopoietic progenitor cell count determined by the SE-automated hematology analyzer with CD34(+) cell count by flow cytometry in leukapheresis products
K U Park, S H Kim, C Suh, et al.
ESMO Open
|
January 1, 2022
Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia
Y Cao, S Qin, S Luo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 21, 2013
A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes
S M Lim, H Chang, M J Yoon, et al.
Page
of 52
Search research articles
Search
Showing results (221-230 of 512) with videos related to
Sort By:
Page
of 52
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 14, 2025
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial
K L Jhaveri, P Neven, M L Casalnuovo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2010
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer
A D Seidman, A Brufsky, R H Ansari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 7, 2022
ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)
S Paluch-Shimon, F Cardoso, A H Partridge, et al.
ESMO Open
|
November 19, 2025
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study
J-P Metges, K Kato, J-M Sun, et al.
Breast Cancer Research and Treatment
|
November 15, 2014
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer
C Palmieri, S Cleator, L S Kilburn, et al.
ESMO Open
|
April 10, 2026
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial
G Curigliano, J O'Shaughnessy, F-C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
N Harbeck, S Modi, L Pusztai, et al.
American Journal of Hematology
|
April 3, 2001
Correlation of hematopoietic progenitor cell count determined by the SE-automated hematology analyzer with CD34(+) cell count by flow cytometry in leukapheresis products
K U Park, S H Kim, C Suh, et al.
ESMO Open
|
January 1, 2022
Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia
Y Cao, S Qin, S Luo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 21, 2013
A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes
S M Lim, H Chang, M J Yoon, et al.
Page
of 52